Effect of early administration of tolvaptan on pleural effusion post-hepatectomy

Effect of early administration of tolvaptan on pleural effusion post-hepatectomy - Effect of early administration of tolvaptan on pleural effusion post-hepatectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000051266

Enrollment

136

Registered

2023-06-05

Start date

2019-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cases of hepatectomy

Interventions

Patients were administered 7.5 mg of tolvaptan with 25 mg of spironolactone per day from the post-hepatectomy day 1 to 5. Usual postoperative management

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Consecutive cases of hepatectomy performed between January 2019 and February 2021 (26 months).(Over 20 years old)

Exclusion criteria

Exclusion criteria: Patients with hyperkalemia (>5.5 mEq/L), diabetes insipidus, preoperative blood sodium level of <125 mEq/L or >150 mEq/L, serum creatinine level of >2 mg/dL, difficulties in communication due to psychiatric disorders, patients on dialysis, and those on tolvaptan orally administered before hepatectomy.

Design outcomes

Primary

Measure	Time frame
Pleural effusion volume on post-hepatectomy day 5	—

Countries

Japan

Contacts

Public ContactHiroya Iida

Shiga Medical University Surgery

hiroya@belle.shiga-med.ac.jp077-548-2238

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026